Firma Kuros Biosciences, Autor bei Presse-Blog

Kuros Biosciences‘ MagnetOs Bone Graft Successfully Achieves Three Key Milestones

23. August 202223. August 2022 Firma Kuros BiosciencesForschung und Entwicklungbone, cell, cells, clinical, flex, Gold, graft, kuros, magnetos, patients, posterolateral, project, spinal, spine, with

Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with MagnetOs worldwide Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced Mehr

Kuros Biosciences reports results for the first six months of 2022

9. August 20229. August 2022 Firma Kuros BiosciencesFinanzen / Bilanzenbone, checkmate, chf, fibrin, flex, graft, kuros, magnetos, market, patients, posterolateral, pth, putty, statements, with

Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million Operational highlights FDA cleared MagnetOs Granules for use in expanded spinal indications FDA Mehr

Annual General Meeting of Kuros Biosciences approves all resolutions

9. Juni 2022 Firma Kuros BiosciencesFinanzen / Bilanzenbiosciences, board, bonds, chf, company, financial, klg, kuros, media, report, risks, shareholders, statements, van, with

. Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and Consolidated Financial Statements for the year 2021 Mehr

Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial

31. Mai 2022 Firma Kuros BiosciencesMedizintechnikbone, cell, cells, clinical, ecm, Gold, graft, isass, kuros, magnetos, origin, patients, posterolateral, project, statements

Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs Data will support product approvals at hospitals and within hospital systems Kuros Biosciences (“Kuros” or the “Company”), Mehr

Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.

18. Mai 2022 Firma Kuros BiosciencesFirmeninternbone, cell, ecm, extender, graft, kuros, magnetos, market, packaging, patients, posterolateral, putty, statements, storage, with

Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the commercial launch of Mehr

Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft

27. April 2022 Firma Kuros BiosciencesMedizintechnik??royalty??, bone, checkmate, ecm, fibrin, flex, graft, kuros, magnetos, market, patients, posterolateral, pth, statements, with

. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in posterolateral spine Promising first-in-human data from Phase II trial of Mehr

Kuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications

21. April 2022 Firma Kuros BiosciencesMedizintechnikbma, bone, bony, cells, easypack, extender, flex, graft, kuros, magnetos, patients, posterolateral, putty, statements, with

Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 months Product provides opportunity to de-risk U.S. commercialization plans Kuros Biosciences (“Kuros” or the “Company”), a leader in Mehr

Kuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications

3. Februar 2022 Firma Kuros BiosciencesForschung und Entwicklungbone, bony, data, extender, forward, Gold, graft, implant, kuros, looking, magnetos, market, patients, posterolateral, statements

Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other 510(k)-cleared bone grafts on the market Kuros Biosciences (“Kuros” or Mehr

Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures

20. Januar 2022 Firma Kuros BiosciencesForschung und Entwicklungbone, cells, clinical, energy, fibrin, graft, kuros, market, patients, pth, research, spinal, statements, tibial, with

. Phase II data published in peer-reviewed Journal of Bone and Joint Surgery Healing rate at six months post-surgery was higher than standard of care Significantly de-risks development of Fibrin-PTH for spinal fusion Kuros Biosciences (“Kuros” or the “Company”), a Mehr

Kuros Biosciences reports continued increase in MagnetOs U.S. sales

26. Oktober 202126. Oktober 2021 Firma Kuros BiosciencesFinanzen / Bilanzenaxis, bone, chf, extender, graft, implant, kuros, magnetos, patients, posterolateral, putty, revenues, statements, with, ytd

MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today provided an update Mehr

Autor: Firma Kuros Biosciences